JO2695B1 - Treatment of latent TB - Google Patents
Treatment of latent TBInfo
- Publication number
- JO2695B1 JO2695B1 JO2005194A JOP20050194A JO2695B1 JO 2695 B1 JO2695 B1 JO 2695B1 JO 2005194 A JO2005194 A JO 2005194A JO P20050194 A JOP20050194 A JO P20050194A JO 2695 B1 JO2695 B1 JO 2695B1
- Authority
- JO
- Jordan
- Prior art keywords
- alkyl
- hydrogen
- het
- alkyloxy
- alkylthio
- Prior art date
Links
- 206010065048 Latent tuberculosis Diseases 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- -1 cyano, hydroxy Chemical group 0.000 abstract 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04078529 | 2004-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO2695B1 true JO2695B1 (en) | 2013-03-03 |
Family
ID=36736133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JO2005194A JO2695B1 (en) | 2004-12-24 | 2005-12-06 | Treatment of latent TB |
Country Status (9)
| Country | Link |
|---|---|
| JP (5) | JP2006182755A (enExample) |
| KR (2) | KR101301573B1 (enExample) |
| CN (1) | CN101087608A (enExample) |
| BG (1) | BG66437B1 (enExample) |
| EA (1) | EA009779B1 (enExample) |
| ES (1) | ES2362886T3 (enExample) |
| JO (1) | JO2695B1 (enExample) |
| UA (1) | UA88766C2 (enExample) |
| ZA (1) | ZA200705160B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA97813C2 (uk) * | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
| CN103664877A (zh) * | 2013-12-25 | 2014-03-26 | 重庆医药工业研究院有限责任公司 | 一种喹啉衍生物、其制备方法和应用 |
| CA3016068C (en) * | 2016-03-07 | 2024-02-27 | The Global Alliance For Tb Drug Development, Inc. | Antibacterial compounds and uses thereof |
| CN109384716B (zh) * | 2017-08-11 | 2021-06-29 | 海创药业股份有限公司 | 一种氘代喹啉化合物及其制备和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6075024A (en) * | 1991-11-27 | 2000-06-13 | Sepracor Inc. | Methods for treating infection using optically pure (S)-lomefloxacin |
| DK2301544T3 (da) * | 2002-07-25 | 2013-01-02 | Janssen Pharmaceutica Nv | Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer |
| EP1753427B1 (en) * | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
-
2005
- 2005-06-09 JP JP2005170052A patent/JP2006182755A/ja not_active Withdrawn
- 2005-06-09 EA EA200500802A patent/EA009779B1/ru unknown
- 2005-06-09 BG BG109180A patent/BG66437B1/bg unknown
- 2005-06-09 KR KR1020050049439A patent/KR101301573B1/ko not_active Expired - Lifetime
- 2005-12-06 JO JO2005194A patent/JO2695B1/en active
- 2005-12-08 ES ES05815816T patent/ES2362886T3/es not_active Expired - Lifetime
- 2005-12-08 CN CNA2005800447974A patent/CN101087608A/zh active Pending
- 2005-12-09 UA UAA200511766A patent/UA88766C2/ru unknown
-
2007
- 2007-06-22 ZA ZA200705160A patent/ZA200705160B/xx unknown
-
2012
- 2012-11-12 JP JP2012248469A patent/JP2013049704A/ja not_active Withdrawn
-
2013
- 2013-03-29 KR KR1020130034387A patent/KR20130041872A/ko not_active Withdrawn
-
2015
- 2015-05-01 JP JP2015094241A patent/JP6426530B2/ja not_active Expired - Lifetime
-
2017
- 2017-03-22 JP JP2017056728A patent/JP2017141262A/ja active Pending
- 2017-03-22 JP JP2017055989A patent/JP2017141259A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006182755A (ja) | 2006-07-13 |
| ES2362886T3 (es) | 2011-07-14 |
| JP6426530B2 (ja) | 2018-11-21 |
| ZA200705160B (en) | 2008-09-25 |
| JP2017141262A (ja) | 2017-08-17 |
| BG109180A (bg) | 2006-06-30 |
| JP2017141259A (ja) | 2017-08-17 |
| CN101087608A (zh) | 2007-12-12 |
| EA009779B1 (ru) | 2008-04-28 |
| KR20060073416A (ko) | 2006-06-28 |
| BG66437B1 (bg) | 2014-07-31 |
| KR101301573B1 (ko) | 2013-09-04 |
| JP2015157847A (ja) | 2015-09-03 |
| EA200500802A1 (ru) | 2006-06-30 |
| KR20130041872A (ko) | 2013-04-25 |
| JP2013049704A (ja) | 2013-03-14 |
| UA88766C2 (ru) | 2009-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200637551A (en) | Treatment of latent tuberculosis | |
| MY148241A (en) | Quinoline derivatives as antibacterial agents | |
| HRP20080307T3 (hr) | Uporaba supstituiranih kinolinskih derivata za tretman bolesti uzrokovanih mikobakterijama otpornima na lijekove | |
| TW200744595A (en) | Quinoline derivatives as antibacterial agents | |
| NO20080499L (no) | Kinolinderivater som antibakterielle midler | |
| NO20081068L (no) | Kinolinderivater som antibakterielle midler | |
| WO2005070924A8 (en) | Substituted quinolines and their use as mycobacterial inhibitors | |
| NO20080501L (no) | Kinolinderivater som antibakterielle midler | |
| JO2695B1 (en) | Treatment of latent TB | |
| NO20080481L (no) | Kinolinderivater som antibakterielle midler | |
| TH80291A (th) | การรักษาวัณโรคแฝง |